Creative Medical Technology Holdings, Inc. announced it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent application. The patent is titled “Treatment Of Heart Failure And/Or Post Infarct Pathological Remodeling By Ex Vivo Reprogrammed Immune Cells.” Once granted, this patent will be in effect until at least 2040.
The patent has broad claims to treat patients who are at risk of developing or who already have heart failure with the company’s proprietary ImmCelz product. Some patients who experience a heart attack develop post-infarct pathological remodeling, which can lead to reduced heart function and potentially result in heart failure.
The total treatable heart failure population in the United States is greater than five million patients. Additionally, over six million patients who have chronic chest pain (refractory angina) despite maximal medical and surgical therapy may also benefit from the ImmCelz product. This allowance further strengthens the company's intellectual property portfolio and supports the growth of its regenerative medicine platform.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.